ARS Pharmaceuticals Inc
SPRY
View Detailed Chart
10.310USD
+0.030+0.29%
Close 10/03, 16:00（ET）Quotes delayed by 15 min
1.02BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.29%
5 Days
+5.20%
1 Month
-3.55%
6 Months
-19.45%
Year to Date
-2.27%
1 Year
-27.34%
View Detailed Chart
TradingKey Stock Score of ARS Pharmaceuticals Inc
Currency: USD Updated: 2025-10-03Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ARS Pharmaceuticals Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
31.333
Target Price
+203.91%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ARS Pharmaceuticals Inc Highlights
StrengthsRisks
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 6674.24% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 89.15M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -21.30, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 85.47M shares, decreasing 5.16% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 105.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.06.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
ARS Pharmaceuticals Inc Info
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Ticker SymbolSPRY
CompanyARS Pharmaceuticals Inc
CEOMr. Richard E. Lowenthal
Websitehttps://ars-pharma.com/
Related Instruments
+1.06%
+0.89%
+1.08%
-0.38%
+2.85%
+0.94%
+2.68%
+2.64%
+0.48%
-0.69%
+1.53%
+1.10%
-3.05%
+0.94%
+2.31%
+1.20%
-1.47%
+1.39%
+2.21%
+1.16%Popular Symbols
